Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 324Carcinoma, Non-Small-Cell Lung 73Skin Neoplasms 66Carcinoma, Renal Cell 50Lung Neoplasms 46Breast Neoplasms 46Colorectal Neoplasms 44Neoplasms 41Carcinoma, Basal Cell 41Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 36Uveal Melanoma 35Ovarian Neoplasms 34Carcinoma, Merkel Cell 32Sarcoma 31Lymphoma, T-Cell, Cutaneous 31Pancreatic Neoplasms 27Prostatic Neoplasms 25Head and Neck Neoplasms 23Stomach Neoplasms 21Carcinoma, Hepatocellular 21Thyroid Neoplasms 20Urinary Bladder Neoplasms 19Uterine Cervical Neoplasms 18Esophageal Neoplasms 18Carcinoma, Squamous Cell 18Brain Neoplasms 17Mycosis Fungoides 16Carcinoma, Transitional Cell 16Recurrence 15

Interventions

Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Melanoma × Dermatologic × 90 days × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡